Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cogstate Limited (CGS.AX)
AUD2.76
-0.02 (-0.72%)
AU ASX Healthcare Medical - Healthcare Information Services
Address
161 Collins Street 3000
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
Bradley John O'Connor
Website
cogstate.com
IPO
2004-02-12
ISIN AU000000CGS8
Also trades on
Australian Securities Exchange · CGS.AX (AUD)
Other OTC · COGZF (USD)
Description
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD2.76
-0.02 (-0.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
197.4K
Beta
0.13
Float Shares
93.49M
Free Float %
54.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -3.41% | +2.82% | +11.35% | -1.16% | +12.83% | +94.66% | +58.39% | +181.77% | +229.92% | +423.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.76
DCF (Unlevered)
3.45
+24.9%
DCF (Levered)
5.16
+86.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
21.08
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%-23.3% Q4'25: -5.1% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+23.5% Q4'25: +48.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+17.2% ★ Q4'25: +9.7% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+27.5% ★ Q4'25: +14.0% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%+78.6% ★ Q4'25: +68.5% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.5% Q4'25: +1.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.04× ★ Q4'25: 0.03× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 3 EPS Ana. |
Jun 2027 3 Rev. Ana. 3 EPS Ana. |
Jun 2028 3 Rev. Ana. 3 EPS Ana. |
Jun 2029 1 Rev. Ana. |
Jun 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.30M
est: 13.82M (-11.0%)
|
11.37M
est: 12.93M (-12.0%)
|
11.55M
est: 12.35M (-6.5%)
|
12.33M
est: 17.34M (-28.9%)
|
27.25M
est: 28.19M (-3.3%)
|
35.01M
est: 36.17M (-3.2%)
|
37.37M
est: 40.20M (-7.0%)
|
30.53M
est: 56.72M (-46.2%)
|
33.97M
est: 34.31M (-1.0%)
|
43.82M
est: 43.54M (+0.6%)
|
62.03M
est: 65.19M (-4.8%)
|
60.14M
est: 59.56M (+1.0%)
|
66.27M
est: 62.86M (+5.4%)
|
50.81M
est: 80.48M (-36.9%)
|
83.58M
83.30M – 83.86M
+3.9% YoY
|
94.51M
93.43M – 95.53M
+13.1% YoY
|
112.85M
111.98M – 113.67M
+19.4% YoY
|
131.32M
130.30M – 132.27M
+16.4% YoY
|
146.35M
145.23M – 147.42M
+11.5% YoY
|
| EBITDA |
3.63M
est: 3.05M (+19.2%)
|
-948.3K
est: 2.69M (-135.2%)
|
-3.86M
est: -1.63M (-136.3%)
|
-3.35M
est: 3.82M (-187.6%)
|
1.57M
est: -3.67M (+142.8%)
|
542.1K
est: 870.3K (-37.7%)
|
1.07M
est: 8.86M (-87.9%)
|
-4.80M
est: 12.50M (-138.4%)
|
-1.22M
est: 824.2K (-248.4%)
|
8.21M
est: 9.60M (-14.5%)
|
18.07M
est: 14.37M (+25.8%)
|
8.46M
est: 13.13M (-35.6%)
|
9.90M
est: -3.97M (+349.3%)
|
16.93M
est: 17.74M (-4.5%)
|
18.42M
18.36M – 18.48M
+3.9% YoY
|
20.83M
20.59M – 21.05M
+13.1% YoY
|
24.87M
24.68M – 25.05M
+19.4% YoY
|
28.94M
28.72M – 29.15M
+16.4% YoY
|
32.25M
32.00M – 32.49M
+11.5% YoY
|
| EBIT |
2.91M
est: 2.26M (+29.0%)
|
-1.46M
est: 2.69M (-154.3%)
|
-4.21M
est: -1.62M (-159.2%)
|
-3.91M
est: 2.83M (-238.2%)
|
824.9K
est: -3.65M (+122.6%)
|
-567.8K
est: 870.3K (-165.2%)
|
233.2K
est: 6.56M (-96.4%)
|
-5.27M
est: 9.26M (-156.9%)
|
-1.93M
est: 824.2K (-333.7%)
|
7.92M
est: 7.11M (+11.4%)
|
10.78M
est: 10.64M (+1.3%)
|
3.09M
est: 9.72M (-68.2%)
|
7.15M
est: -3.97M (+280.2%)
|
13.98M
est: 13.14M (+6.4%)
|
13.65M
13.60M – 13.69M
+3.9% YoY
|
15.43M
15.26M – 15.60M
+13.1% YoY
|
18.43M
18.28M – 18.56M
+19.4% YoY
|
21.44M
21.28M – 21.60M
+16.4% YoY
|
23.90M
23.71M – 24.07M
+11.5% YoY
|
| Net Income |
2.51M
est: 6.58M (-61.9%)
|
-1.79M
est: 2.37M (-175.5%)
|
-3.66M
est: -1.92M (-90.7%)
|
-3.88M
est: -2.05M (-89.8%)
|
2.64M
est: -4.32M (+161.2%)
|
-853.1K
est: 2.21M (-138.5%)
|
-730.4K
|
-3.49M
est: 3.93M (-188.8%)
|
-2.92M
est: 2.10M (-239.2%)
|
7.02M
est: 3.48M (+101.8%)
|
10.37M
est: 10.72M (-3.3%)
|
5.30M
est: 1.83M (+190.0%)
|
5.45M
est: 5.45M (+0.0%)
|
10.14M
est: 14.69M (-30.9%)
|
17.29M
15.44M – 19.15M
+17.8% YoY
|
21.62M
18.93M – 24.31M
+25.0% YoY
|
29.30M
22.05M – 36.55M
+35.5% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
7.81M
est: 3.11M (+150.7%)
|
6.73M
est: 5.64M (+19.2%)
|
7.62M
est: 8.47M (-10.1%)
|
7.77M
est: 3.91M (+98.9%)
|
9.80M
est: 19.05M (-48.5%)
|
12.78M
est: 11.87M (+7.7%)
|
13.92M
est: 9.06M (+53.7%)
|
13.94M
est: 12.78M (+9.1%)
|
8.59M
est: 11.24M (-23.6%)
|
10.37M
est: 9.81M (+5.6%)
|
11.84M
est: 14.69M (-19.4%)
|
14.49M
est: 13.42M (+7.9%)
|
13.63M
est: 19.10M (-28.7%)
|
12.86M
est: 20.61M (-37.6%)
|
18.84M
18.78M – 18.90M
-8.6% YoY
|
21.30M
21.06M – 21.53M
+13.1% YoY
|
25.44M
25.24M – 25.62M
+19.4% YoY
|
29.60M
29.37M – 29.81M
+16.4% YoY
|
32.99M
32.73M – 33.23M
+11.5% YoY
|
| EPS |
0.03
est: 0.04 (-11.9%)
|
-0.02
est: 0.00 (-1,291.1%)
|
-0.04
est: -0.26 (+84.3%)
|
-0.04
est: -0.01 (-232.5%)
|
0.02
est: 0.02 (-2.1%)
|
-0.01
est: 0.00 (-1,338.2%)
|
-0.01
|
-0.03
est: 0.02 (-229.7%)
|
-0.02
est: -0.02 (+21.3%)
|
0.04
est: 0.02 (+102.7%)
|
0.06
est: 0.06 (-2.6%)
|
0.03
est: 0.01 (+191.1%)
|
0.05
est: 0.04 (+16.5%)
|
0.06
est: 0.08 (-29.9%)
|
0.10
0.09 – 0.11
+15.2% YoY
|
0.12
0.11 – 0.14
+24.4% YoY
|
0.16
0.13 – 0.21
+30.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
31.83M
OE per share TTM
0.18
Owner's Yield
7.29%
Maintenance CapEx ratio
9.64%
Maint CapEx / Avg PPE
4.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
95.1K
Shares Outstanding
170.99M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bradley John O'Connor | Chief Executive Officer, MD & Executive Director | 2M | male |
| Rachel Colite | Executive Vice President of Clinical Trials | 784.5K | female |
| Pamela Ventola | Chief Science Officer | 753.9K | — |
| Darren Watson | Chief Financial Officer | 732.7K | male |
| Kenneth Billard | Chief Commercial Officer | 582.1K | male |
| Paul Maruff BBSc | Founder & Chief Innovation Officer | — | — |
| Kristi Geddes | General Counsel, Joint Company Secretary & Director | — | female |
| Kaycee Sink | Chief Medical Officer | — | — |
| David James Franks | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGS.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
